The Conversation (0)
Moleculin Biotech announced the appointment of Dr. Sandra Silberman as their chief medical officers, who will be in charge of new products.
Moleculin Biotech (NASDAQ:MBRX) announced the appointment of Dr. Sandra Silberman as their chief medical officers, who will be in charge of new products.
As quoted in the press release:
“Dr. Silberman is a highly experienced, well-esteemed oncologist and CMO,” commented Walter Klemp, Chairman and CEO of Moleculin. “Among her many accomplishments, she was the project leader for Gleevec, a blockbuster cancer drug. We’ve benefitted from her guidance during her time on our Science Advisory Board, but as we have gained momentum with our WP1066 and WP1122 Portfolios, we now need the focus of a highly qualified CMO. We are honored to have such an accomplished physician leading these planned clinical projects.”
Mr. Klemp concluded, “This appointment allows Dr. Robert Shepard, our CMO in charge of Hematology, to devote his full attention to the clinical trials of Annamycin.”
Click here to read the full press release.
Source: www.marketwired.com
